Exacerbations and Real-World Outcomes After Single-Inhaler Triple Therapy of Budesonide/Glycopyrrolate/Formoterol Fumarate, Among Patients with COPD: Results from the EROS (US) Study.

"Disclosure SS, SP, DE, NF, and MP are employees of AstraZeneca and hold AstraZeneca stock. JT, JS, BL, and BA are employees of Inovalon, who received funding from AstraZeneca to conduct this study. DRT, EP, and CS are paid consultants of AstraZeneca. DRT reports personal fees from Stage Analytics, eMax Health, Horizon Pharmaceuticals, Monument Analytics; grants from Takeda Pharmaceuticals, outside the submitted work. CS reports personal fees from AlphaNet, Adverum, CSL Behring, Morair, UpToDate, GlaxoSmithKline; grants from Arrowhead, OCI, Pandorum, Pulmanage, Takeda, Vertex, NuVaira, CSA Medical, Grifols, Pulmonx, and AstraZeneca, outside the submitted work. The authors report no other conflicts of interest in this work."

"This study was sponsored by AstraZeneca."